Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19
Detection Principle
ImmunoAssay-Antibody
Target
IgM/IgG
Testing Method Category
Mixed
Testing Method
Immunochromatography and CT assays
Reported Performance
Sensitivity: 27.8% (IgM 1 week), 48% (IgM 1-2 weeks), 95.8% (IgM >2 weeks), 3.3% (IgG 1 week), 8% (IgG 1-2 weeks), 62.5% (IgG >2 weeks), 57.9% (CT asymptomatic), 68.4% (CT combined with IC asymptomatic), 74.3% (CT symptomatic), 82.4% (CT combined with IC symptomatic)
Sample Size
112 patients with COVID-19 and 48 non-COVID-19 patients
Peer-reviewed
yes
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements